How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

MG

NASDAQ:MGNX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

MG

MacroGenics IncNASDAQ MGNX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is MGNX undervalued compared to its fair value?

The fair value of MGNX stock is hidden USD. Relative to the market price of 4.92 USD MacroGenics Inc is hidden.

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-as...[More about valuation]

MacroGenics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.314 $B

Price:

4.92 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.838

FINANCIALS

MacroGenics financial for reporting period

Income Statement

0.0091 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.054 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.052 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0091 B 100%
0.007 B 77%
-0.054 B -590%
-0.052 B -573%

Balance Sheet

0.25 B
0.11 B

Financial Position Analysis

Assets

0.25 B
Current Assets
0.2 B
Total non-current assets
0.046 B

Total current liabilities
0.056 B
Total non-current liabilities
0.086 B

Cash Flow Statement

-0.047 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.046 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

MacroGenics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-15 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-832 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-8 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is MGNX attractive for investment based on fundamental analysis?

MGNX stock rating is hidden. MacroGenics is a hidden by Eyestock methodology.

Get MGNX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-53

Gross Margin:

84

CFO / Debt ratio:

hidden

Current ratio:

4.799

Debt / Equity ratio:

ROE:

-15

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

MGNX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for MGNX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

MacroGenics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

MacroGenics Inc dividends

MGNX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About MGNX stock

About the company MacroGenics Inc

Market cap $B

0.314

Dividend yield

Shares outstanding

61.8386 B

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

MGNX profile

  • Ticker

    MGNX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    10 October 2013

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    357

  • City

    Rockville

  • Address

    9704 Medical Center Drive

  • Cusip

    556099109